<?xml version='1.0' encoding='utf-8'?>
<document id="23110788"><sentence text="Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole."><entity charOffset="49-67" id="DDI-PubMed.23110788.s1.e0" text="ulipristal acetate" /><entity charOffset="132-144" id="DDI-PubMed.23110788.s1.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.23110788.s1.e0" e2="DDI-PubMed.23110788.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23110788.s1.e0" e2="DDI-PubMed.23110788.s1.e1" /></sentence><sentence text="Ulipristal acetate is a novel selective progesterone receptor modulator for the treatment of benign gynecological conditions such as uterine myoma"><entity charOffset="0-18" id="DDI-PubMed.23110788.s2.e0" text="Ulipristal acetate" /><entity charOffset="40-52" id="DDI-PubMed.23110788.s2.e1" text="progesterone" /><pair ddi="false" e1="DDI-PubMed.23110788.s2.e0" e2="DDI-PubMed.23110788.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23110788.s2.e0" e2="DDI-PubMed.23110788.s2.e1" /></sentence><sentence text=" As a Biopharmaceutical Classification System (BCS) II compound, it is highly soluble at low pH but has low solubility at neutral conditions" /><sentence text=" Esomeprazole, a proton pump inhibitor used widely for treatment of gastric and duodenal ulcers, efficiently increases gastric pH"><entity charOffset="1-13" id="DDI-PubMed.23110788.s4.e0" text="Esomeprazole" /></sentence><sentence text=" Thus, the aim of this study was to determine the effects of esomeprazole on the pharmacokinetics of ulipristal acetate"><entity charOffset="61-73" id="DDI-PubMed.23110788.s5.e0" text="esomeprazole" /><entity charOffset="101-119" id="DDI-PubMed.23110788.s5.e1" text="ulipristal acetate" /><pair ddi="false" e1="DDI-PubMed.23110788.s5.e0" e2="DDI-PubMed.23110788.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23110788.s5.e0" e2="DDI-PubMed.23110788.s5.e1" /></sentence><sentence text="" /><sentence text="This was a nonrandomized, single sequence, 2 period, open, study in 18 healthy female subjects" /><sentence text=" Subjects received oral ulipristal acetate tablets (10 mg) once on Days 1 and 13 and daily esomeprazole administrations (20 mg) from Days 9 through 14"><entity charOffset="24-42" id="DDI-PubMed.23110788.s8.e0" text="ulipristal acetate" /><entity charOffset="91-103" id="DDI-PubMed.23110788.s8.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.23110788.s8.e0" e2="DDI-PubMed.23110788.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23110788.s8.e0" e2="DDI-PubMed.23110788.s8.e1" /></sentence><sentence text="" /><sentence text="Co-administration of esomeprazole decreased geometric mean Cmax of ulipristal acetate by 65% (geometric mean ratio point estimate (90% CI): 0"><entity charOffset="21-33" id="DDI-PubMed.23110788.s10.e0" text="esomeprazole" /><entity charOffset="67-85" id="DDI-PubMed.23110788.s10.e1" text="ulipristal acetate" /><pair ddi="false" e1="DDI-PubMed.23110788.s10.e0" e2="DDI-PubMed.23110788.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23110788.s10.e0" e2="DDI-PubMed.23110788.s10.e1" /></sentence><sentence text="35 (0" /><sentence text="28 - 0" /><sentence text="42)), and delayed median tmax from 0" /><sentence text="75 to 1" /><sentence text="00 h (Hodges-Lehmann estimate of difference (90% CI): tmax 0" /><sentence text="63 (0" /><sentence text="25 - 1" /><sentence text="25)) but had minor effects on AUCs of +15% and +11% (geometric mean ratio point estimates (90% CI): AUC0-t 1" /><sentence text="15 (1" /><sentence text="02 - 1" /><sentence text="31) and AUC0-âˆž (1" /><sentence text="11 (0" /><sentence text="98 - 1" /><sentence text="27)), respectively" /><sentence text=" A total of 6 adverse events were reported by 4 subjects, none of them being serious" /><sentence text="" /><sentence text="Concomitant use of ulipristal acetate with esomeprazole at therapeutic concentrations led to a modified absorption rate while exposure in terms of AUC remained close to bioequivalence limits"><entity charOffset="19-37" id="DDI-PubMed.23110788.s27.e0" text="ulipristal acetate" /><entity charOffset="43-55" id="DDI-PubMed.23110788.s27.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.23110788.s27.e0" e2="DDI-PubMed.23110788.s27.e0" /><pair ddi="false" e1="DDI-PubMed.23110788.s27.e0" e2="DDI-PubMed.23110788.s27.e1" /></sentence><sentence text=" In the context of chronic administration of ulipristal acetate, no clinically significant effects are expected from co-administration with drugs increasing gastric pH"><entity charOffset="45-63" id="DDI-PubMed.23110788.s28.e0" text="ulipristal acetate" /></sentence><sentence text="" /></document>